08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Dexisometheptene mucate: Development discontinued

Tonix said it will discontinue development of TNX-201 after top-line data from a double-blind, U.S. Phase II trial in 147 patients with episodic tension-type headache showed that a single 140 mg dose of oral TNX-201...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Clinical News

Dexisometheptene mucate: Completed Phase II enrollment

Tonix completed enrollment of over 200 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating a single dose of 140 mg oral TNX-201 given when a tension-type headache occurs. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP),...